The enigma of the clandestine association between chloroquine and HIV-1 infection

HIV Medicine

Volumn 16, Issue 10, 2015, Pages 585-590

  Chauhan, A ^a   Tikoo, A ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chloroquine; Endocytosis; HIV 1; Immune activation; Non CD4 cells

Indexed keywords

CHLOROQUINE; ANTIMALARIAL AGENT;

ANTIVIRAL THERAPY; ASTROCYTE; CD4+ T LYMPHOCYTE; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE DEPLETION; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; ANIMAL; AUTOIMMUNITY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

ANIMALS; ANTIMALARIALS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CHLOROQUINE; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84945469588     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12295     Document Type: Review

References (50)

1. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008; 20: 33-47.
2. Laskey SB, Siliciano RF. A mechanistic theory to explain the efficacy of antiretroviral therapy. Nat Rev Microbiol 2014; 12: 772-780.
3. Chen MF, Gill AJ, Kolson DL. Neuropathogenesis of HIV-associated neurocognitive disorders: roles for immune activation, HIV blipping and viral tropism. Curr Opin HIV AIDS 2014; 9: 559-564.
4. Harada S, Maeda Y. Chemically induced infection of CD4-negative HeLa cells with HIV-1. Microbiol Immunol 1999; 43: 1077-1086.
5. Vidricaire G, Tremblay MJ. Rab5 and Rab7, but not ARF6, govern the early events of HIV-1 infection in polarized human placental cells. J Immunol 2005; 175: 6517-6530.
6. Vijaykumar TS, Nath A, Chauhan A. Chloroquine mediated molecular tuning of astrocytes for enhanced permissiveness to HIV infection. Virology 2008; 381: 1-5.
7. Chauhan A, Mehla R, Theophilus-Sunder VK, Handy I. Endocytosis-mediated HIV-1 entry and its significance in the elusive behavior of the HIV-1 in astrocytes. Virology 2014; 456-457: 1-19.
8. Kamya MR, Kigonya CN, McFarland W. HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children. AIDS 2001; 15: 1187-1188.
9. Singh K, Moran A, Story W, Bailey P, Chavane L. Acknowledging HIV and malaria as major causes of maternal mortality in Mozambique. Int J Gynaecol Obstet 2014; 127: 35-40.
10. Duvignaud A, Denoeud-Ndam L, Akakpo J etal. Incidence of malaria-related fever and morbidity due to Plasmodium falciparum among HIV1-infected pregnant women: a prospective cohort study in South Benin. Malar J 2014; 13: 255.
11. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011; 7: 718-729.
12. Taherian E, Rao A, Malemud CJ, Askari AD. The biological and clinical activity of anti-malarial drugs in autoimmune disorders. Curr Rheumatol Rev 2013; 9: 45-62.
13. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006; 6: 67-69.
14. Savarino A. Use of chloroquine in viral diseases. Lancet Infect Dis 2011; 11: 653-654.
15. Paton NI, Goodall RL, Dunn DT etal. Hydroxychloroquine Trial Team. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012; 308: 353-361.
16. Vaccari M, Fenizia C, Ma ZM etal. Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques. AIDS Res Hum Retroviruses 2014; 30: 355-362.
17. Routy JP, Angel J, Patel M etal. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune non-responding HIV-infected patients receiving antiretroviral therapy. HIV Med 2015; 16: 48-56.
18. Naarding MA, Baan E, Pollakis G, Paxton MA. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4 positive T-lymphocytes. Retrovirology 2007; 30: 4-6.
19. Savarino A, Lucia MB, Rastrelli E etal. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 2004; 35: 223-232.
20. Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV. Inhibition of endosomal/ lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol 2002; 76: 11440-11446.
21. Hunt PW, Martin JN, Sinclair E etal. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543.
22. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794-4804.
23. Beignon AS, McKenna K, Skoberne M etal. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005; 115: 3265-3275.
24. Kawai T, Sato S, Ishii KJ etal. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004; 5: 1061-1068.
25. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
26. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
27. Barrat FJ, Meeker T, Gregorio J etal. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202: 1131-1139.
28. Marshak-Rothstein A. Tolling for autoimmunity-prime time for 7. Immunity 2006; 25: 397-399.
29. Schmidt B, Ashlock BM, Foster H, Fujimura SH, Levy JA. HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology 2005; 343: 256-266.
30. Brenchley JM, Price DA, Schacker TW etal. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
31. Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother 2010; 54: 871-881.
32. Kristoff J, Haret-Richter G, Ma D etal. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest 2014; 124: 2802-2806.
33. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007; 20: 160-174.
34. Murray SM, Down CM, Boulware DR etal. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010; 84: 12082-12086.
35. Macfarlane DE, Manzel L. Antagonism of immunostimulatoryCpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998; 160: 1122-1131.
36. Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998; 160: 4755-4761.
37. Weber SM, Chen JM, Levitz SM. Inhibition of mitogen-activated protein kinase signaling by chloroquine. J Immunol 2002; 168: 5303-5309.
38. Mackenzie AH. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med 1983; 75: 5-10.
39. Hellgren U, Kihamia CM, Mahikwano LF, Björkman A, Eriksson O, Rombo L. Response of Plasmodium falciparum to chloroquine treatment: relation to whole blood concentrations of chloroquine and desethyl-chloroquine. Bull World Health Organ 1989; 67: 197-202.
40. Hugosson E, Björkman A, Troye-Blomberg M. Chloroquine enhances the number of IL-10 producing cells and the expression of B7-2 and ICAM-1 in in-vitro-cultured PBMC. Scand J Immunol 2002; 55: 399-408.
41. Cepika AM, SoldoJureša D, MorovićVergles J etal. Decrease in circulating DNA, IL-10 and BAFF levels in newly-diagnosed SLE patients after corticosteroid and chloroquine treatment. Cell Immunol 2012; 276: 196-203.
42. Pardridge WM, Yang J, Diagne A. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol Lett 1998; 64: 45-47.
43. Piconi S, Parisotto S, Rizzardini G etal. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011; 118: 3263-3272.
44. French JK, Hurst NP, O'Donnell ML, Betts WH. Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy. Ann Rheum Dis 1987; 46: 42-45.
45. Telgt DS, van der Ven AJ, Schimmer B, Droogleever-Fortuyn HA, Sauerwein RW. Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection. Ann Pharmacother 2005; 39: 551-554.
46. Schneider C, Adamcova M, Jick SS etal. Use of anti-malarial drugs and the risk of developing eye disorders. Travel Med Infect Dis 2014; 12: 40-47.
47. Chiang G, Sassaroli M, Louie M, Chen H, Stecher VJ, Sperber K. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther 1996; 18: 1080-1092.
48. Clarke JN, Lake JA, Burrell CJ, Wesselingh SL, Gorry PR, Li P. Novel pathway of human immunodeficiency virus type 1 uptake and release in astrocytes. Virology 2006; 348: 141-155.
49. Schaeffer E, Soros VB, Greene WC. Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J Virol 2004; 78: 1375-1383.
50. Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum 2013; 43: 264-272.